CiteFacts · FDA Drug Shortages · FDA source
FDA shortage status: Cefotaxime Sodium Powder, for Solution
FDA source answer
FDA currently lists this ingredient in shortage.
FDA source statuses: Current. First FDA posting: 2015-02-17. Latest FDA row update: 2026-09-18.
FDA lists 6 package records, with companies: Hikma Pharmaceuticals USA Inc., Hikma Pharmaceuticals USA, Inc., SteriMax Inc., SteriMax, Inc.. Package NDCs: 0143-9930-10, 0143-9931-25, 0143-9933-25, 0143-9935-01, 21586-011-02, 21586-012-02.
FDA shortage reason: Demand increase for the drug
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Package NDC | Presentation | FDA availability field | FDA update |
|---|---|---|---|---|
| Hikma Pharmaceuticals USA, Inc. | 0143-9931-25 | Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 0143-9931-25) | Unavailable | 2026-09-18 |
| Hikma Pharmaceuticals USA, Inc. | 0143-9935-01 | Cefotaxime Sodium, Powder, for Solution, 10 g (NDC 0143-9935-01) | Unavailable | 2026-09-18 |
| Hikma Pharmaceuticals USA, Inc. | 0143-9933-25 | Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 0143-9933-25) | Unavailable | 2026-09-18 |
| Hikma Pharmaceuticals USA, Inc. | 0143-9930-10 | Cefotaxime Sodium, Powder, for Solution, 500 mg (NDC 0143-9930-10) | Unavailable | 2026-09-18 |
| SteriMax, Inc. | 21586-011-02 | Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 21586-011-02) | Available | 2026-06-15 |
| SteriMax, Inc. | 21586-012-02 | Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 21586-012-02) | Available | 2026-06-15 |
Source facts
Grouped generic ingredient: Cefotaxime Sodium Powder, for Solution · 6 package records
Therapeutic categories: Anti-Infective, Pediatric
Dosage forms: Powder, For Solution
Routes: INTRAMUSCULAR, INTRAVENOUS
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-10-06T18:55:41+00:00. Derived grouping is documented in this record's derivations.